Cramer Remix: The two key stocks I'm watching

Cramer: The two key stocks I'm watching

Friday was a good example of everything that can happen when things go right on the stock market. It was a work of true beauty, in Jim Cramer's eyes. The monthly job report had just enough growth without inflation, calm oil, a boring dollar and strong earnings. A great Friday!

However, there were also some huge takeaways from this action. In preparation for a new week, Cramer outlined the lessons below.

First, the market will hit just when you least expect it. As soon as you are so pessimistic that you're ready to sell everything and the charts look like everything will implode, BOOM. That's when it rallies.

Second, interest rates have finally peaked for 2015. They've done nothing but rise for the year, but now there is no real inflation and Europe is doing better. If the European economy is starting to grow, then why the heck would our rates be much higher than them?

Third, if Europe is really as strong as Cramer thinks, then he expects American companies will do much better overseas. Just take one look at McDonald's when it announced a positive surprise in Europe on Friday morning.

Lastly, Cramer reminded investors that the right time to buy is when companies give you a discount. Pretend you're in the supermarket and want the best price! When all of the traders are freaking out, that is the time to buy.

So, now that everyone is on the same page, Cramer revealed the top stocks that he will be watching next week:

Monday: Actavis
Cramer considers this to be perhaps the most important healthcare company out there. If Actavis blows away the estimates, then he expects everything in healthcare to rally. It's one of the most important reports of the week!

Wednesday: Macy's, Ralph Lauren, J.C. Penney, Shake Shack, Cisco
Cisco: Cramer expects that the incoming CEO Chuck Robbins will build on the momentum created by outgoing CEO John Chambers. It remains a core position for Cramer's charitable trust.

Read More Cramer game plan: Traders must worry about this

Dusty McCoy, chairman and CEO of Brunswick Corp.
Adam Jeffery | CNBC

With the sunshine and warm weather returning to the East Coast, Cramer has been thinking about summer time—and his 17-foot Boston Whaler.

Brunswick Corp is the world's top maker of recreational boats and boat engines, with a side leg dedicated to billiards tables and fitness machines.

The company reported last week and missed Wall Street's estimates, partially because they took a hit from the strong dollar and partially because it invested heavily to generate future growth. As a result, investors sunk the stock 7 percent in a single session last Wednesday.

"At these levels, I think Brunswick is darned cheap," the "Mad Money" host said.

Could this be the perfect summer stock play? To find out, Cramer sat down with Brunswick CEO Dusty McCoy.

"We look around the world and one of the things we try not to do is whine about currency. We've left our thesis intact; our guidance has not changed. We're just going to have to deal with this," McCoy added.

Read More Cramer: Tesla engine for your boat? Done!

There is no doubt to Cramer that Whole Foods is a great place to shop. But with those same-store-sales numbers reported on Wednesday, what the heck is he supposed to do with the stock?

"I left work last night puzzled and unsatisfied about how to deal with Whole Foods after its hideous decline. Sometimes a company defies its stock, and sometimes a stock defies its company, and I fear this is one of those times," the "Mad Money" host said.

Cramer loves the experience of walking around his local Whole Foods in Brooklyn. While some may complain that it's too expensive, he only thinks consumers are paying up for the prepared foods, which taste great and are still cheaper than going to a restaurant.

However, Whole Foods' same-store-sales figure of less than 3 percent obviously disappointed investors, and the stock was hit hard.

So, what the heck do you use to measure Whole Foods? The same-store-sales metric has always been key because it can show organic growth by discounting new locations that need time to grow.

At this point, Cramer is completely puzzled. This Whole Foods fiasco has made him question his own methodologies. Maybe it needs that new, smaller-store concept, or maybe the same store measurement is still good and the stock just needs to take a beating.

Either way, Cramer has deduced that this stock is not a bargain, and until it can demonstrate consistent growth, he will not recommend it.

Read More Cramer: What the heck to do with Whole Foods

A man walks into a Whole Foods Market in Brooklyn, New York.
Getty Images

Another stock that could be hot this summer is La Quinta. It was taken public a little over a year ago and has been gaining steady ground ever since, up 44 percent from its IPO price of $17.

The company reported a strong quarter and delivered in-line earnings and better-than-expected revenues, which prompted the stock to hit a new all-time high last Thursday.

What Cramer has always liked about La Quinta is that it is a rapidly growing hotel chain, expanding all over the U.S. and Latin America.

With gas prices fluctuating and more travelers hitting the road this summer, could the stock bring the heat, too? To find out, Cramer spoke with its CEO Wayne Goldberg.

"We see some real positive outlook for this peak summer season for travel…So, we feel very good that a lot of folks are driving, and that a lower gas price is a still a net tailwind, not a headwind, for our business," Goldberg said.

Another stock on Cramer's radar is Radius Health, a company focused on developing drugs for osteoporosis and other endocrine-mediated disorders. It came public in June last year at $8, and skyrocketed to its peak at $51 approximately three months ago.

Since then, the stock has been taken to the woodshed with the biotech space, and it is down nearly 25 percent from its February highs. Could there be exciting months ahead for the stock? Cramer sat down with Radius Health CEO Robert Ward to find out.

The CEO commented on the positive outlook for its investigational drug abaloparatide, which serves women with severe osteoporosis.

"Most important medicines launch around the world within the first year of launch. We are really focused on the US, so we want a partner for globalizing abaoloparitide," Ward said.

In the Lightning Round, Cramer gave his take on a few caller favorite stocks:

3D Systems Corporation: "Nope. Still too early to buy 3D systems. I don't like that group."

Opko Health: "You want to own OPK, and if the stock comes in on the earnings call you want to do some buying."

Read More Lightning Round: Nope. Still too early to buy this